Optimi Health Corp. (OPTH) — Optimi Health completed another export of 5mg psilocybin capsules, about 1,000 capsules, to Australia for treatment-resistant depression patients, its third commercial shipment since launching the product in September 2025.
The recurring shipments demonstrate steady demand and Optimi's ability to reliably supply the regulated Australian prescription market. The order flow supports the commercial-stage manufacturer's revenue base.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.